It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2013
  5. 7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist

February 8, 2013

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist

Tokyo, Japan, February 8, 2013 - Otsuka Pharmaceutical Co., Ltd. today announced that Samsca® (tolvaptan), vasopressin V2 receptor antagonist indicated for the treatment of volume overload in patients with heart failure, was granted additional approval of tablets in 7.5mg dosage on February 4, 2013.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases